Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke

Stroke

Volumn 34, Issue 4, 2003, Pages 1038-1040

  Montaner, Joan ^a   Ribó, Marc ^a   Monasterio, Jasone ^a   Molina, Carlos A ^a   Alvarez Sabín, José ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Carboxypeptidase U; Cerebral ischemia; Stroke; TAFI; Thrombolysis

Indexed keywords

THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SYMPTOM;

ACUTE DISEASE; BRAIN ISCHEMIA; CARBOXYPEPTIDASE U; CEREBROVASCULAR ACCIDENT; DISEASE PROGRESSION; HUMANS;

EID: 0037383184     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000063139.06585.45     Document Type: Article

References (10)

1. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1995;270:14477-14484.
2. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176-27181.
3. Mosnier LO, von dem Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost. 1998;80:829-835.
4. Silveira A, Schatteman K, Goossens F, Moor E, Scharpe S, Stromqvist M, Hendriks D, Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000;84:364-368.
5. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 2000;95:2855-2859.
6. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Interphysician agreement in the diagnosis of subtypes of acute ischemic stroke: implications for clinical trials: the TOAST Investigators. Neurology. 1993;43:1021-1027.
7. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet. 1991;337:1521-1526.
8. Mead GE, Lewis SC, Wardlaw JM, Dennis MS, Warlow CP. How well does the Oxfordshire Community Stroke Project classification predict the site and size of the infarct on brain imaging? J Neurol Neurosurg Psychiatry. 2000;68:558-562.
9. Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156-2161.
10. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res. 2000;98:333-342.